StockData
Adagio Medical Holdings, Inc. logo

Adagio Medical Holdings, Inc. (ADGM) company profile

ADGMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 2/30
$1.65+0.04 (+2.48%)

Close on Nov 17, 2026Market cap $1.37MP/E –Yield –

About Adagio Medical

Surgical & Medical Instruments & Apparatus, SIC 3841

Adagio Medical is a medical device company that develops and commercializes catheter-based systems for treating cardiac arrhythmias, focusing primarily on ventricular tachycardia. Its core offerings include the vCLAS Cryoablation System and Ultra-Low Temperature Ablation console, which use pressurized, near-critical liquid nitrogen to create deep, durable lesions in cardiac tissue without fluid irrigation. The company also develops pulsed field cryoablation technologies combining ultracold cryoablation with pulsed field energy. These medical solutions are designed for electrophysiologists, cardiac catheterization laboratories, and hospital ablation centers treating patients affected by ventricular tachycardia, structural heart disease, and atrial fibrillation.

The company operates internationally through regulatory clinical trial networks and commercial authorization pathways. Its clinical studies encompass dozens of investigative medical centers across the United States, Canada, and the European Union. Its initial cryoablation system holds European CE Mark approval and investigational clearance in the United States, supported by a global intellectual property portfolio. The company's headquarters are not stated in the provided text.

Summary of the business section of Adagio Medical's latest annual report, written by StockData.

Company profile

Company

Legal name
Adagio Medical Holdings, Inc.
Headquarters
Laguna Hills, CA
Address
26051 Merit Circle, Suite 102 92653
Phone
(949) 348-1188
Employees
41, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
WithumSmith+Brown, PC, Whippany, New Jersey

Stock & identifiers

Ticker
ADGM
Exchange
Nasdaq
IPO date
Aug 1, 2024
Shares outstanding
22M, Aug 10, 2026
Public float
$7, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-30 reverse, Nov 16, 2026; 779908-for-1, Nov 14, 2024
SEC CIK
2006986
CUSIP
00534B100
ISIN
US00534B1008
FIGI
BBG01P202S42
Share class FIGI
BBG01P202S60
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Todd UsenChief Executive Officer, Director207,315
Deborah KasterChief Financial Officer15,000
Dan GeorgeInterim CFO–
Keyvan Mirsaeedi-FarahaniDirector12,770
Sandra A. GardinerDirector–
Orly MishanDirector–
Sean SalmonDirector–
James L. CoxDirector36,698
Timothy P. MoranDirector–
Advisors Llc PerceptiveDirector9,876,586
Life Sciences LLC C2Director–

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 41 full-time employees, located in the U.S.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?